Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: Results from a single-centre cohort study

Colorectal Disease

Volumn 15, Issue 1, 2013, Pages 27-33

  Feng, J P ^a   Yuan, X L ^a   Li, M ^a   Fang, J ^a   Xie, T ^a   Zhou, Y ^b   Zhu, Y M ^a   Luo, M ^a   Lin, M ^a   Ye, Da Wei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

5 fluorouracil; Colorectal cancer; Diabetes; Toxicity

Indexed keywords

ANTIDIABETIC AGENT; FLUOROURACIL; FOLINIC ACID; GLUCOSE; IRINOTECAN; MITOMYCIN; OXALIPLATIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; PHYSIOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ANTIMETABOLITES, ANTINEOPLASTIC; C-PEPTIDE; COLORECTAL NEOPLASMS; DIABETES MELLITUS; FEMALE; FLUOROURACIL; FOOD HABITS; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PHYSICAL THERAPY MODALITIES; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84871667848     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2012.03097.x     Document Type: Article

References (22)

1. Cunningham D, Sirohi B, Pluzanska A et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 244-50.
2. Marcuello E, Paez D, Pare L et al. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer 2011; 105: 53-7.
3. Davies JM, Goldberg RM. Treatment of metastatic colorectal cancer. Semin Oncol 2011; 38: 552-60.
4. Nozawa H, Kitayama J, Sunami E et al. FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer. Oncology 2011; 80: 84-91.
5. Vincenzi B, Schiavon G, Pantano F, Santini D, Tonini G. Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. Nat Clin Pract Oncol 2008; 5: 455-65.
6. Tayek JA, Chlebowski RT. Metabolic response to chemotherapy in colon cancer patients. JPEN J Parenter Enteral Nutr 1992; 16: 65S-71S.
7. Köhne CH, Harstrick A, Hiddemann W et al. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study. Eur J Cancer 1997; 33: 1896-9.
8. Weiser MA, Cabanillas ME, Konopleva M et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 2004; 100: 1179-85.
9. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.4.0 2010. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40 (accessed on 15 December 2011).
10. Choo V. WHO reassesses appropriate body-mass index for Asian populations. Lancet 2002; 360: 235.
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
12. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011; 34(Suppl 1): S62-9.
13. Giouleme O, Diamantidis MD, Katsaros MG. Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J Gastroenterol 2011; 17: 444-8.
14. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 1679-87.
15. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800, 000 individuals. BMC Cancer 2011; 11: 20.
16. Wang ZZ, Huang XZ, Tang SB et al. The prevalence of NIDDM and IGT and related factors among residents in some areas of Hubei Province, China. Biomed Environ Sci 2000; 13: 148-53.
17. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009; 15: 469-74.
18. Saigi I, Perez A. [Management of glucocorticoid induced hyperglycemia]. Rev Clin Esp 2010; 210: 397-403.
19. Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am 1999; 25: 489-505.
20. Volgi JR, Baldwin D Jr.. Glucocorticoid therapy and diabetes management. Nurs Clin North Am 2001; 36: 333-9, viii.
21. Saag KG, Koehnke R, Caldwell JR et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 115-23.
22. Komdeur R, Derksen J, Legdeur MC, Hylkema BS. Cisplatin-induced hyperglycemic hyperosmolar coma. Neth J Med 2007; 65: 36-7.